Diamonds and Dogs

7/13/18

Galmed Pharmaceuticals(GLMD) upgraded again. After rallying 13% yesterday on an upgrade from Cantor Fitzgerald with a price target of $59, Galmed Pharma is up 18% today on an upgrade from Stifel with a $35 target. Stifel believes Galmed's lead, wholly-owned asset Aramchol has proven itself in a recent P2b trial (ARREST) as a clearly active and very safe compound for treating NASH, a highly unmet medical need and projected multi-billion dollar market opportunity.

Department of Justice giving AT&T (T) headaches. AT&T is down 2% not far from a 52 week low on news the government would appeal the merger's approval of AT&T and Time Warner. The initial approval of the deal was expected to spur a wave of deals in the telecom and media industries. Raymond James downgraded AT&T this morning to a neutral from a buy, saying the DOJ's appeal is "a negative catalyst for the stock," calling it "a frustrating delay."

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.